324 related articles for article (PubMed ID: 28910151)
1. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ
Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of
Wong P; Li L; Chea J; Delgado MK; Crow D; Poku E; Szpikowska B; Bowles N; Channappa D; Colcher D; Wong JYC; Shively JE; Yazaki PJ
Nucl Med Biol; 2017 Apr; 47():62-68. PubMed ID: 28126683
[TBL] [Abstract][Full Text] [Related]
3. Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.
Li L; Crow D; Turatti F; Bading JR; Anderson AL; Poku E; Yazaki PJ; Carmichael J; Leong D; Wheatcroft D; Raubitschek AA; Hudson PJ; Colcher D; Shively JE
Bioconjug Chem; 2011 Apr; 22(4):709-16. PubMed ID: 21395337
[TBL] [Abstract][Full Text] [Related]
4.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
5. Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.
Li L; Turatti F; Crow D; Bading JR; Anderson AL; Poku E; Yazaki PJ; Williams LE; Tamvakis D; Sanders P; Leong D; Raubitschek A; Hudson PJ; Colcher D; Shively JE
J Nucl Med; 2010 Jul; 51(7):1139-46. PubMed ID: 20554731
[TBL] [Abstract][Full Text] [Related]
6. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
[TBL] [Abstract][Full Text] [Related]
8. ImmunoPET Imaging of α
White JB; Hu LY; Boucher DL; Sutcliffe JL
Mol Imaging Biol; 2018 Feb; 20(1):103-113. PubMed ID: 28653240
[TBL] [Abstract][Full Text] [Related]
9. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
10. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
11. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA).
Moon SH; Yang BY; Kim YJ; Hong MK; Lee YS; Lee DS; Chung JK; Jeong JM
Nanomedicine; 2016 May; 12(4):871-879. PubMed ID: 26739097
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of a
Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
[TBL] [Abstract][Full Text] [Related]
13. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.
Li L; Yazaki PJ; Anderson AL; Crow D; Colcher D; Wu AM; Williams LE; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2006; 17(1):68-76. PubMed ID: 16417253
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
[TBL] [Abstract][Full Text] [Related]
15. Tumor uptake of pegylated diabodies: Balancing systemic clearance and vascular transport.
Li Q; White JB; Peterson NC; Rickert KW; Lloyd CO; Allen KL; Rosenthal K; Gao X; Wu H; Dall'Acqua WF; Borrok MJ; Tsui P
J Control Release; 2018 Jun; 279():126-135. PubMed ID: 29653224
[TBL] [Abstract][Full Text] [Related]
16. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
[TBL] [Abstract][Full Text] [Related]
18. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin.
Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY
Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
